Revolution Medicines, Inc. (NASDAQ:RVMD) Holdings Cut by Casdin Capital LLC

Casdin Capital LLC reduced its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 10.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,699,283 shares of the company's stock after selling 415,000 shares during the period. Revolution Medicines makes up 10.8% of Casdin Capital LLC's portfolio, making the stock its 3rd biggest holding. Casdin Capital LLC owned about 2.20% of Revolution Medicines worth $161,807,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc bought a new stake in shares of Revolution Medicines during the 4th quarter valued at about $34,000. Sterling Capital Management LLC grew its stake in Revolution Medicines by 588.7% in the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock worth $86,000 after buying an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock worth $90,000 after buying an additional 1,613 shares during the last quarter. Kapitalo Investimentos Ltda purchased a new stake in shares of Revolution Medicines during the 4th quarter valued at $104,000. Finally, Daiwa Securities Group Inc. lifted its holdings in shares of Revolution Medicines by 521.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after acquiring an additional 3,178 shares during the last quarter. Institutional investors own 94.34% of the company's stock.

Insider Activity at Revolution Medicines

In other news, CFO Jack Anders sold 1,864 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares in the company, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the sale, the chief operating officer now owns 153,533 shares in the company, valued at approximately $5,993,928.32. This represents a 1.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock valued at $650,406 in the last three months. Company insiders own 8.00% of the company's stock.

Revolution Medicines Trading Down 2.3 %

Shares of Revolution Medicines stock opened at $39.79 on Tuesday. The company's fifty day simple moving average is $37.33 and its two-hundred day simple moving average is $43.62. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $62.40. The company has a market cap of $7.41 billion, a P/E ratio of -11.08 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). Analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RVMD has been the subject of several research analyst reports. UBS Group lifted their price target on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Stifel Nicolaus cut their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright lifted their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Needham & Company LLC reaffirmed a "buy" rating and issued a $59.00 price objective on shares of Revolution Medicines in a research note on Tuesday, April 8th. Finally, Wedbush reiterated an "outperform" rating and issued a $67.00 target price on shares of Revolution Medicines in a research report on Monday, April 28th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $66.67.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.